Study Comparing IBI363 and Docetaxel for Advanced Squamous Lung Cancer After Standard Treatments Have Failed

Inclusion Criteria

• Must be willing to sign a consent form and follow the study schedule and procedures.
• Must be 18 years or older.
• Have advanced or metastatic squamous non-small cell lung cancer that cannot be removed by surgery.
• Cancer must have resisted or returned after standard treatments, including platinum-based chemotherapy and PD-1/PD-L1 immunotherapy.
• Must show cancer progression on scans during or within 6 months after stopping PD-1/PD-L1 treatment.
• Agree to provide a tumor sample for testing.
• Have at least one measurable tumor on a scan.
• Be in good general health with an ECOG performance status of 0 or 1.
• Expected to live at least 3 more months.
• Women of childbearing potential and men with partners of childbearing potential must use effective birth control during and for 6 months after treatment.
• Women must not breastfeed during and for 6 months after treatment.

Exclusion Criteria

• Women who are pregnant or breastfeeding, or planning to become pregnant during or within 6 months after treatment.
• Have certain genetic mutations that have approved targeted treatments.
• Have active or untreated brain metastases, unless stable for at least 4 weeks after treatment.
• Have certain blood or liver test abnormalities.
• Have a history of serious blood clots or bleeding issues.
• Have significant heart or lung diseases.
• Have uncontrolled infections or other serious medical conditions.
• Have a history of severe allergic reactions to study drugs.
• Have not recovered from previous cancer treatments or surgeries.
• Have other active cancers, except for certain skin or prostate cancers.
• Have received certain medications or treatments that are not allowed in the study.